Tamoxifen treatment of UTXFDC/FDC female mice has a strong influence on hematopoietic parameters
| Parameter . | Unit . | Marker . | Tissue . | Tamoxifen pre/without . | Tamoxifen post/with . | P value . |
|---|---|---|---|---|---|---|
| RBC | ×1012 L−1 | Peripheral blood | 10.7 ± 0.8 | 8.5 ± 1.1 | * | |
| Hb | g dL−1 | Peripheral blood | 16.8 ± 1.1 | 14.3 ± 1.9 | † | |
| Platelets | ×109 L−1 | Peripheral blood | 830 ± 68 | 417 ± 122 | * | |
| WBC | ×109 L−1 | Peripheral blood | 18.6 ± 3.0 | 10.7 ± 1.6 | † | |
| Erythroid cells | % | CD45−Ter119+ | Bone marrow | 28.4 ± 7.2 | 3.7 ± 1.5 | * |
| Erythroid precursor | % | CD45−Ter119+CD71+ | Bone marrow | 15.2 ± 3.6 | 2.7 ± 1.1 | * |
| Erythroid precursor | % | CD45−Ter119+CD71+ | Spleen | 17.4 ± 2.3 | 34.2 ± 10.5 | .07 |
| B cells | % | CD45+CD19+B220+ | Spleen | 24.2 ± 3.7 | 11.8 ± 2.8 | * |
| Parameter . | Unit . | Marker . | Tissue . | Tamoxifen pre/without . | Tamoxifen post/with . | P value . |
|---|---|---|---|---|---|---|
| RBC | ×1012 L−1 | Peripheral blood | 10.7 ± 0.8 | 8.5 ± 1.1 | * | |
| Hb | g dL−1 | Peripheral blood | 16.8 ± 1.1 | 14.3 ± 1.9 | † | |
| Platelets | ×109 L−1 | Peripheral blood | 830 ± 68 | 417 ± 122 | * | |
| WBC | ×109 L−1 | Peripheral blood | 18.6 ± 3.0 | 10.7 ± 1.6 | † | |
| Erythroid cells | % | CD45−Ter119+ | Bone marrow | 28.4 ± 7.2 | 3.7 ± 1.5 | * |
| Erythroid precursor | % | CD45−Ter119+CD71+ | Bone marrow | 15.2 ± 3.6 | 2.7 ± 1.1 | * |
| Erythroid precursor | % | CD45−Ter119+CD71+ | Spleen | 17.4 ± 2.3 | 34.2 ± 10.5 | .07 |
| B cells | % | CD45+CD19+B220+ | Spleen | 24.2 ± 3.7 | 11.8 ± 2.8 | * |
Blood values of Tamoxifen-treated UTXFDC/FDC female mice in comparison with animals without or before treatment. Mean and standard deviation of data from ≥6 mice are shown. Hb, hemoglobin; RBC, red blood cell count; WBC, white blood cell count.
P < .01; †P < .05.